TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04987190

Intervention type: PROCEDURE
Intervention: alveolar bone graft
Description: alveolar bone graft with Scarpa fascia done when patients were at 9 year of age
Study: NCT06205641

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Xuanfei Baidu Granule Placebo
Description: Take Xuanfei Baidu Granule Placebo 1 bag in the morning and evening with boiling water for 5 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Xuanfei Baidu Granule
Description: Take Xuanfei Baidu Granule 1 bag in the morning and evening with boiling water for 5 days.
Study: NCT06682871

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Analgesia
Description: Postoperatively, patients will be given analgesia
Study: NCT06619548

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Auricular magnet with a magnetic strength of 1800 Gauss
Description: Auricular magnets with a magnetic strength of 1800 Gauss are used as the experimental group.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Auricular magnet with a magnetic strength of 1800 Gauss
Description: Auricular magnets with a magnetic strength of 1800 Gauss are used as the experimental group.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Auricular magnet with no magnetic strength
Description: Auricular magnets with no magnetic strength are used as placebo control.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Auricular magnet with no magnetic strength
Description: Auricular magnets with no magnetic strength are used as placebo control.
Study: NCT04857814

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ADAMM- RSM Device
Description: All participants will wear the ADAMM- RSM device for a 6 month period
Study: NCT06375616

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nafamostat Mesylate
Description: During RRT, a priming dose of 20 mg of nafamostat mesylate (NM) is administered before initiation of the procedure. Upon starting the machine, there is no loading dose, but a maintenance infusion rate of 25 mg/h of NM is maintained. NM is discontinued in the last half hour before the end of the RRT session.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Unfractionated Heparin
Description: During RRT, a priming dose of 50 mg of unfractionated heparin (UFH) is administered before initiation of the procedure. Upon starting the machine, a loading dose of 0.2 mg/kg of UFH is given, followed by a maintenance infusion rate of 0.1 mg/kg/h of UFH. The anticoagulant is discontinued in the last half hour before the end of the RRT session.
Study: NCT05026099

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Boxing training
Description: Boxing training: warm-up. Mitt hitting, sandbag hitting, in sitting, cool down, Assessment after 4 weeks boxing training: warm-up. Mitt hitting, sandbag hitting, below hips, cool down, Assessment after 6 weeks Boxing training: warm-up. Mitt hitting, sandbag hitting, both inn sitting and standing, cool down, Post assessment

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Task Oriented Training
Description: Task-oriented training: 6 tasks in sitting and standing position for both upper and lower limb Assessment after 4 weeks Task oriented training: 6 tasks in sitting and standing position for both upper and lower limb Assessment after 6 weeks Task oriented training: 6 tasks in sitting and standing position for both upper and lower limb Post assessment
Study: NCT05341336

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: total surgical excision
Description: patients will be operated under general anesthesia. Pressure is applied along the incision line while staying away from the palpable margin of the AVM lesion and used Raney clips to control bleeding.~Once the skin flap was raised, the lesion could be seen through the galea. The galea around the lesion is incised, and the lesion will be separated from the underlying skin using a combination of bipolar diathermy and sharp dissection.~The nidus is often located in galeal aponeurosis. Dilated arteries and veins extended into subcutaneous tissue, which was separated with special care to prevent accidental nidus rupture and avoid excessive cauterization to prevent postoperative scalp necrosis.~Ligation is applied on feeder arteries, then applied to veins with total excision of the lesion.~After excision of the lesion, the skin flap was replaced with interrupted stitches.~The wound was allowed to heal primarily along with intravenous administration of antibiotics.
Study: NCT06243601

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Aloe vera Gel
Description: A fresh aloe vera (Aloe Barbadensis) leaf will be plucked from the plant. The leaf will be washed with normal saline, peeled with scalpel and the inner gel will be blended in a blender to convert it into a watery consistency. The solution will be stored in an autoclaved flask.
Study: NCT05942105

Intervention type: PROCEDURE
Intervention: Breast conservative surgery
Description: Breast conservative surgery after non-palpable lesion localization

Intervention type: PROCEDURE
Intervention: Breast conservative surgery
Description: Breast conservative surgery after non-palpable lesion localization

Intervention type: PROCEDURE
Intervention: Breast conservative surgery
Description: Breast conservative surgery after non-palpable lesion localization

Intervention type: PROCEDURE
Intervention: Breast conservative surgery
Description: Breast conservative surgery after non-palpable lesion localization
Study: NCT05948566

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TS23
Description: Monoclonal antibody

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TS23
Description: Monoclonal antibody

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TS23
Description: Monoclonal antibody

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TS23
Description: Monoclonal antibody

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: TS23
Description: Monoclonal antibody
Study: NCT05243342

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XmAb24306
Description: XmAb24306 will be given via intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XmAb24306
Description: XmAb24306 will be given via intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: Participants will receive daratumumab via subcutaneous (SC) injection every week for Cycles 1-4, every 2 weeks for Cycles 5-12, and every 4 weeks thereafter (cycle length = 2 weeks for Cycles 1-12 and 4 weeks thereafter)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: Participants will receive daratumumab via subcutaneous (SC) injection every week for Cycles 1-4, every 2 weeks for Cycles 5-12, and every 4 weeks thereafter (cycle length = 2 weeks for Cycles 1-12 and 4 weeks thereafter)
Study: NCT05113641

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Alkalizing Fruit and Vegetables
Description: The weekly deliveries will contain combinations of fresh, frozen, and dried fruits and vegetables, as well as juices and soups which have been selected for their negative potential renal acid load (PRAL) values and shelf-life. All participants will be started at a F+V intake equal to -30 to -40 mEq per day reduction in dietary acid load estimated by the PRAL equation. Participants serum bicarbonate concentration will be measured at 1 month, and at 3 months, those with values \< 22 mEq/L will have their recommended amount of F+V increased to -40 to -50 mEq per day. If a participant's 1- or 3-month serum bicarbonate value exceeds 29 mEq/L, their target dose of F+V in mEq/d will be reduced by 25%.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium bicarbonate
Description: Study nephrologist will prescribe the oral alkali therapy (sodium bicarbonate) and the medications will be dispensed by the Seven Oaks Hospital pharmacy.
Study: NCT06359171

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Application ARTH-e
Description: The ARTH-e application must be downloaded via the PlayStore or Applestore platform on phone and/or tablet. Once the application has been downloaded, the patient must scan a QRcode sent by the CHU to anonymize the data.~Participants will have 6 months to use the application at their convenience.
Study: NCT05659979

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Comprehensive geriatric assessment
Description: A detailed comprehensive geriatric assessment will be given to all the participants randomized to this group, including the administration of multidimensional prognostic index (MPI), a tool derived from the CGA and consisting of eight different domains.
Study: NCT06391541

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: modified thoracolumbar interfacial plan block (mTLIP)
Description: Injecting local anesthetic at L3 vertebral level between the longisimus and iliocostalis muscles within the erector spinae muscles.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intertransverse process block (ITP)
Description: injection of local anesthetic on the superior costotransverse ligament between the transverse process and the pleura.
Study: NCT05738551

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: stress ball
Description: Applicable to group 1

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: chewing gum
Description: Applicable to group 2
Study: NCT05797415

Intervention type: PROCEDURE
Intervention: Sentinel Lymph Node Biopsy
Description: * Injection of 99mTc-labeled nanocolloids~* Preoperative lymphoscintigraphy~* Intraoperative gamma probe search of the sentinel lymph node~* Sentinel lymph node biopsy~* Excisional biopsy of the neoformation in cases not undergoing excision before SLN biopsy.~* If the SLN is histologically positive, the multidisciplinary team will consider whether to refer the patient for parotidectomy and excision of the lymph node chain and/or adjuvant radio/chemotherapy.

Intervention type: PROCEDURE
Intervention: Sentinel Lymph Node Biopsy
Description: * Injection of 99mTc-labeled nanocolloids~* Preoperative lymphoscintigraphy~* Intraoperative gamma probe search of the sentinel lymph node~* Sentinel lymph node biopsy~* Excisional biopsy of the neoformation in cases not undergoing excision before SLN biopsy.~* If the SLN is histologically positive, the multidisciplinary team will consider whether to refer the patient for parotidectomy and excision of the lymph node chain and/or adjuvant radio/chemotherapy.

Intervention type: PROCEDURE
Intervention: Sentinel Lymph Node Biopsy
Description: * Injection of 99mTc-labeled nanocolloids~* Preoperative lymphoscintigraphy~* Intraoperative gamma probe search of the sentinel lymph node~* Sentinel lymph node biopsy~* Excisional biopsy of the neoformation in cases not undergoing excision before SLN biopsy.~* If the SLN is histologically positive, the multidisciplinary team will consider whether to refer the patient for parotidectomy and excision of the lymph node chain and/or adjuvant radio/chemotherapy.

Intervention type: PROCEDURE
Intervention: Sentinel Lymph Node Biopsy
Description: * Injection of 99mTc-labeled nanocolloids~* Preoperative lymphoscintigraphy~* Intraoperative gamma probe search of the sentinel lymph node~* Sentinel lymph node biopsy~* Excisional biopsy of the neoformation in cases not undergoing excision before SLN biopsy.~* If the SLN is histologically positive, the multidisciplinary team will consider whether to refer the patient for parotidectomy and excision of the lymph node chain and/or adjuvant radio/chemotherapy.

Intervention type: PROCEDURE
Intervention: Sentinel Lymph Node Biopsy
Description: * Injection of 99mTc-labeled nanocolloids~* Preoperative lymphoscintigraphy~* Intraoperative gamma probe search of the sentinel lymph node~* Sentinel lymph node biopsy~* Excisional biopsy of the neoformation in cases not undergoing excision before SLN biopsy.~* If the SLN is histologically positive, the multidisciplinary team will consider whether to refer the patient for parotidectomy and excision of the lymph node chain and/or adjuvant radio/chemotherapy.
Study: NCT06027697

Intervention type: DEVICE
Intervention: AccuFill® Porous Bone Substitute Material (BSM)
Description: The patient will undergo a minimally invasive surgery procedure (subchondroplasty) to receive the medical device AccuFill® Porous Bone Substitute Material (BSM).
Study: NCT06278753

Intervention type: DIAGNOSTIC_TEST
Intervention: carbon dioxide cystoscopy
Description: Using carbon dioxide medium for filling bladder
Study: NCT05619718

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Awareness, Courage, and Love Groups
Description: Groups based on the Awareness, Courage, and Love framework from functional analytic psychotherapy

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mutual Help Meetings
Description: Groups based on treatment as usual where patients gather to discuss how they can help others on the ward, and make requests for how others can help them.
Study: NCT06466876

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: retrieval-based word learning
Description: Word learning intervention that compares two strategies for teaching novel words
Study: NCT04697004

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Investigational Arm: SMR Stemless Reverse
Description: The SMR Stemless Reverse is intended for total, primary shoulder joint replacement by reducing pain and restoring shoulder articular mobility function.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Control Arm: SMR Reverse Shoulder System
Description: Conventional stemmed shoulder prostheses are commonly used in the clinical practice.
Study: NCT05831696

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Powered Microprocessor-controlled Knee (PMPK)
Description: A microprocessor-controlled Knee with standardized commercial prosthetic foot
Study: NCT05709353

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prolonged exposure therapy
Description: COPE represents an integration of existing evidence-based manualised CBT interventions for PTSD and substance dependence (see manual DOI: 10.1093/med:psych/9780199334513.001.0001). COPE used in the current study will represent an integration of existing evidence-based manualised CBT interventions for PTSD and substance dependence. COPE only begins when the participant in a safe environment and no longer in contact with the traumatic event/exposure.~COPE employs imaginal and in vivo exposures to treat PTSD and consists of 12 individual 90-minute sessions (i.e. 19.5 hours) delivered by a clinical psychologist.
Study: NCT06205641

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xuanfei Baidu Granule
Description: Take Xuanfei Baidu Granule 1 bag in the morning and evening with boiling water for 5 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Baloxavir Marboxil Tablet
Description: Take Baloxavir Marboxil Tablet 2 tablets orally, once a day, for 1 day.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Baloxavir Marboxil Tablet
Description: Take Baloxavir Marboxil Tablet 2 tablets orally, once a day, for 1 day.
Study: NCT05709353

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Prolonged exposure therapy
Description: COPE represents an integration of existing evidence-based manualised CBT interventions for PTSD and substance dependence (see manual DOI: 10.1093/med:psych/9780199334513.001.0001). COPE used in the current study will represent an integration of existing evidence-based manualised CBT interventions for PTSD and substance dependence. COPE only begins when the participant in a safe environment and no longer in contact with the traumatic event/exposure.~COPE employs imaginal and in vivo exposures to treat PTSD and consists of 12 individual 90-minute sessions (i.e. 19.5 hours) delivered by a clinical psychologist.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MDMA
Description: Administration of 80 to 160 mg MDMA across two 'dosing' sessions. Supplemental doses (additional 40mg during first session, additional 40- 80mg during second session) will be dependent on clinician and participant consensus during preparatory period of 'dosing session'. These supplemental amounts will be dispensed 60 to 90 minutes after initial 80 mg dose.

Intervention type: DRUG
Group type: OTHER
Intervention: Niacin
Description: Administration of niacin 250mg or niacin-matched placebo during two 'dosing' sessions.
Study: NCT05429164

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Self Myofascial Release
Description: In the self-myofascial release technique, a tennis ball will be placed on the 4th rib on the shoulder side to be applied on the wall, and the participants will be asked to move the ball using their body along the pectoralis minor.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Myofascial Release
Description: A slight caudal force will be applied by the physiotherapist until the pectoralis minor muscle meets the comfortable elastic limit of the soft tissue.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Instrument Assisted Soft Tissue Mobilization
Description: Instrument-assisted soft tissue mobilization will be performed with the specified instruments for the pectoralis minor muscle.
Study: NCT05146960

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Temporal summation
Description: Temporal summation will be evoked in each predetermined area

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: PPTs will be assessed once in each predetermined area
Study: NCT06038903

Intervention type: OTHER
Intervention: caffeine consumption expectation
Description: The group to which the Short-form caffeine expectation questionnaire (B-CaffeQ) was applied, which evaluated the expectations from caffeine consumption.

Intervention type: OTHER
Intervention: caffeine consumption expectation
Description: The group to which the Short-form caffeine expectation questionnaire (B-CaffeQ) was applied, which evaluated the expectations from caffeine consumption.
Study: NCT06236360

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mediterranean Diet Intervention
Description: The primary goal is to evaluate whether tele-intervention can elevate the level of flavonoids, anthocyanins, proteins, omega-3 fatty acids, short fatty acids, fruits and vegetables, and fibers (all previously associated with a better response to immunotherapy) and limit foods with added sugars.
Study: NCT05739032

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic exercise and strength training
Description: Aerobic Exercise Training: The individuals in the study group were given aerobic exercise training at 70-80% of the 6MWT average speed. Patients performed exercise three days per week (twice under the supervision of a physiotherapist and once at home) for 30 minutes a day.~Strength Training: Lower and upper extremity strengthening training was performed three days a week, 3x10-12 repetitions per day, with the help of a resistance band suitable for muscle strength. Hip flexion, hip abduction, knee flexion, and knee extension exercises for the lower extremity, and shoulder flexion, shoulder extension, shoulder abduction, shoulder elevation, external rotation, horizontal shoulder abduction, and scapular adduction exercises for the upper extremity were performed.
Study: NCT04868643

Intervention type: DEVICE
Group type: OTHER
Intervention: The DIMI Renal Replacement Therapy (RRT) System
Description: To demonstrate that the safety and efficacy of the DIMI RRT remains consistent when used In-Center by trained dialysis nurses versus in an In-Home environment by trained Care Partners and Subjects.

Intervention type: DEVICE
Group type: OTHER
Intervention: The DIMI Renal Replacement Therapy (RRT) System
Description: To demonstrate that the safety and efficacy of the DIMI RRT remains consistent when used In-Center by trained dialysis nurses versus in an In-Home environment by trained Care Partners and Subjects.
Study: NCT06408922

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: prp injection
Description: intraarticular prp

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: prp injection
Description: intraarticular prp
Study: NCT04873297

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metoclopramide 10mg
Description: Tab. Metoclopramide 10mg TDS via NG tube

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 10 ml of plain water Via NG
Study: NCT05114161

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Novel Care Pathway
Description: The novel care pathway will follow a decision tree based on several criteria to stratify patients in an appropriate risk category. Patients with large radiographic lobar consolidation OR POC CRP \> 60mg/L will be deemed 'appreciable risk' while patients with CRP \< 20mg/L will be deemed 'low risk'. Patients with CRP between 20 - 60mg/L will be evaluated further, as follows: if they have an oxygen saturation of \<95%, they will be 'appreciable risk', and if not, there are further decision points: if they are not tachypneic, they will be 'low risk'; if they are tachypneic and less than 1 year of age, they will be 'appreciable risk'; if they are tachypneic, over 1 year of age, but with either complete PCV13 immunization OR detectable wheezing as per the ED clinician, they will be classified as 'low risk'. Appreciable-risk participants will be given a prescription for antibiotics at ED discharge.